AUSTRALIA’s first guidelines for the diagnosis and management of atrial fibrillation (AF) – an increasingly prevalent heart arrythmia which heightens the risk of stroke – have been developed by the National Heart Foundation of Australia (NHF) and the Cardiac Society of Australia and New Zealand (CSANZ) and summarised in the Medical Journal of Australia.
International guidelines on AF do exist, but according to the authors of the new recommendations, “individual recommendations may differ, and no guidelines have previously been developed specific to the Australian population”.
Led by Professor David Brieger, the large group of experts working with the NHF and the CSANZ, developed the guidelines “to assist Australian clinicians in the diagnosis and management of adult patients with AF”, using “recent evidence interpreted by local experts to optimise application in an Australian context”.
Changes in management as a result of the guidelines include:
- Opportunistic screening in the clinic or community is recommended for patients over 65 years of age.
- The importance of deciding between a rate and rhythm control strategy at the time of diagnosis and periodically thereafter is emphasised; beta-blockers or non-dihydropyridine calcium channel antagonists remain the first line choice for acute and chronic rate control; cardioversion remains the first line choice for acute rhythm control when clinically indicated; flecainide is preferable to amiodarone for acute and chronic rhythm control; failure of rate or rhythm control should prompt consideration of percutaneous or surgical ablation.
- The sexless CHA2DS2-VA score is recommended to assess stroke risk, which standardises thresholds across men and women; anticoagulation is not recommended for a score of 0, and is recommended for a score of ≥ 2; if anticoagulation is indicated, non-vitamin K oral anticoagulants are recommended in preference to warfarin.
- An integrated care approach should be adopted, delivered by multidisciplinary teams, including patient education and the use of eHealth tools and resources where available; regular monitoring and feedback of risk factor control, treatment adherence and persistence should occur.
Guidelines for the prevention, detection and management of heart failure (HF) have been updated and a summary is also published today by the Medical Journal of Australia.
Replacing the 2011 NHF/CSANZ guidelines, they have been “designed to facilitate the systematic integration of recommendations into HF care”.
“This should include ongoing audit and feedback systems integrated into work practices in order to improve the quality of care and outcomes of patients with HF,” wrote the authors, led by Dr John Atherton, Director of Cardiology at the Royal Brisbane and Women’s Hospital. The NHF and CSANZ funded and coordinated the development of the new heart failure guidelines..
Executive summaries of both sets of new guidelines can be found at http://www.mja.com.au
The full clinical guidelines for AF can be found at https://doi.org/10.1016/j.hlc.2018.06.1043
The full clinical guidelines for HF can be found at https://doi.org/10.1016/j.hlc.2018.06.1042
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.